Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Share-based Compensation of $44.3 million for Q1 2026, up 104.75% year-over-year from $21.6 million in Q1 2025, and up 13702.18% quarter-over-quarter from $321000.0 in Q4 2025.
Amneal Pharmaceuticals (AMRX) Share-based Compensation (2018 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Share-based Compensation history runs 9 years deep, the most recent figure standing at $44.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 104.75% year-over-year to $44.3 million; the TTM figure through Mar 2026 stood at $44.9 million (up 96.53% YoY), while the FY2025 annual figure was $22.3 million, up 180.16% from the prior year.
- Share-based Compensation for Q1 2026 stood at $44.3 million, up from $321000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $44.3 million in Q1 2026, with the low at -$12.6 million in Q4 2024.
- The 5-year median for Share-based Compensation is $6.6 million (2023), against an average of $6.2 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation slumped 1829.71% in 2022, then jumped 6688.64% in 2023.
- Amneal Pharmaceuticals' Share-based Compensation stood at $88000.0 in 2022, then surged by 6688.64% to $6.0 million in 2023, then sank by 311.01% to -$12.6 million in 2024, then soared by 102.55% to $321000.0 in 2025, then surged by 13702.18% to $44.3 million in 2026.
- Business Quant data shows AMRX's Share-based Compensation at $44.3 million in Q1 2026, $321000.0 in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Amneal Pharmaceuticals | 5.72 Bn | 5.59 Bn | 334.51 Mn | 176,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 176,000.00 |
| Jun 30, 2026 | 176,000.00 |
| Mar 31, 2026 | 44.31 Mn |
| Mar 31, 2026 | 44.31 Mn |
| Dec 31, 2025 | 321,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 6.43 Mn |
| Sep 30, 2025 | 6.43 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | 21.64 Mn |
| Mar 31, 2025 | 21.64 Mn |
| Dec 31, 2024 | -12.61 Mn |
| Dec 31, 2024 | -12.61 Mn |
| Sep 30, 2024 | 7.11 Mn |
| Sep 30, 2024 | 7.11 Mn |
| Jun 30, 2024 | 6.72 Mn |
| Jun 30, 2024 | 6.72 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Mar 31, 2024 | 6.72 Mn |